Paper Details
- Home
- Paper Details
FDA warning montelukast 03.2020-Statement of the Austrian working group of pediatric pulmonology and allergology.
Author: EberErnst, FrischerThomas, HorakFritz, RiedlerJosef, SimmaBurkhardt, StetzlWolfgang, SzépfalusiZsolt, ZacharasiewiczAngela, ZschockeAnna
Original Abstract of the Article :
Montelukast, a leukotriene receptor antagonist (LTRA) has been approved for use in Europe since 1998. Indications for use (from the age of 6 months) include mild to moderate asthma, seasonal allergic rhinitis with asthma, and the prevention of exercise-induced asthma episodes. The psychiatric side e...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1007/s00508-021-01981-1
データ提供：米国国立医学図書館（NLM）
Navigating the Terrain of Montelukast Treatment
Montelukast, a commonly prescribed medication for asthma and allergic rhinitis, has been associated with potential psychiatric side effects. This statement from the Austrian working group of pediatric pulmonology and allergology highlights the need for caution when using montelukast, especially in children. It’s like a seasoned desert explorer carefully navigating a treacherous landscape, aware of the potential dangers and prepared to take necessary precautions.
Weighing the Risks and Benefits
The statement underscores the importance of carefully evaluating the potential risks and benefits of montelukast treatment, especially in children. It’s like meticulously assessing the terrain before embarking on a desert journey, considering the potential challenges and rewards. This guidance emphasizes the need for ongoing monitoring of patients receiving montelukast treatment, ensuring that any potential neuropsychiatric side effects are promptly identified and addressed.
Protecting Children's Mental Health
The statement highlights the importance of prioritizing the mental well-being of children, ensuring that medications are used safely and effectively. It’s like a shepherd carefully tending to their flock, ensuring that each member is safe and well cared for. This guidance encourages clinicians and families to remain vigilant and proactive in monitoring the mental health of children receiving montelukast treatment, ensuring that their well-being is paramount.
Dr. Camel's Conclusion
This statement serves as a valuable reminder for clinicians and families to exercise caution when using montelukast, especially in children. It highlights the importance of careful monitoring and prompt intervention when necessary, ensuring the safe and effective use of this medication. It's like a wise desert guide, providing essential guidance and warnings to help travelers navigate the sometimes treacherous terrain of medication use.
Date :
- Date Completed 2022-02-07
- Date Revised 2022-02-07
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.